Table 2.

IDH1 mutations in glioblastomas clinically diagnosed as primary

IDH1 mutation statusIDH1 mutation −IDH1 mutation +P
No. of cases363 (96.3%)14 (3.7%)
Age (y)60.9 ± 13.350.8 ± 12.10.0054
Male/female ratio1.491.8N.s.
Clinical history* (mo)3.8 ± 10.228.8 ± 74.1<0.0001
Median survival (mo)10.0 (n = 185)31.6 (n = 9)<0.0001
Mean survival (mo)11.3 ± 7.1 (n = 185)30.0 ± 18.7 (n = 9)<0.0001
Genetic alterations
    TP53 mutations87/326 (26.7%)9/12 (75.0%)0.0009
    EGFR amplification114/322 (35.4%)0/14 (0%)0.0033
    p16INK4a deletion82/278 (29.5%)3/10 (30.0%)N.s.
    PTEN mutations66/270 (24.4%)1/10 (10.0%)N.s.
    LOH 1p34/223 (15.2%)1/8 (12.5%)N.s.
    LOH 10q142/216 (65.7%)8/9 (88.9%)N.s.
    LOH 19q9/226 (4.0%)1/7 (14.3%)N.s.

Abbreviations: N.s., not significant; y, years; mo, months.

  • *Time from the first clinical symptom to glioblastoma diagnosis.